-
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
NASDAQ: $CGEM CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases… Source: Read More
-
Zipalertinib Shows Promise in Non-Small Cell Lung Cancer Clinical Trial
NASDAQ: $CGEM A Significant Milestone for Targeted Therapy Recent clinical data has brought a wave of optimism for patients battling non-small cell lung cancer (NSCLC). According to recent reports, the combination of zipalertinib and standard chemotherapy has successfully met its primary endpoint in a planned interim analysis, demonstrating a statistically significant improvement in progression-free survival…